Page 151 - 2019_11 Resto del Mondo-web
P. 151

Rituximab maintenance therapy in CLL
expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia. 2003;17(12):2426-2434.
19. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression- free and overall survival in chronic lympho- cytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30(9):980-988.
20. Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehen- sive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34(31):3758-2765.
21. Greil R, Obrtlíková P, Smolej L, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or sec- ond-line rituximab-containing chemoim-
munotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Lancet Haematol. 2016;3(7):e317-e329.
(ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry B Clin Cytom. 2018;94(1):121-
22. Dimier N, Delmar P, Ward C, et al. A model 128.
for predicting effect of treatment on pro- gression-free survival using MRD as a sur- rogate end point in CLL. Blood. 2018;131(9):955-962.
23. Strati P, Keating MJ, O'Brien SM, et al. Eradication of bone marrow minimal resid- ual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123(24):3727-3732.
24. Thompson PA, Peterson CB, Strati P, et al. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized thera- peutic strategies. Leukemia. 2018;32(11): 2388-2398.
25. Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of chronic lym- phocytic leukemia by flow cytometry: an European Research Initiative on CLL
26. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitor- ing in chronic lymphocytic leukaemia. Leukemia. 2007;21(5):956-964.
27. Rawstron A, Cohen D, de Tute R, et al. Bone marrow is more sensitive than peripheral blood for detection of MRD in CLL and provides a more reliable predic- tion of outcome across different treat- ments. Haematologica. 2015;100(Suppl 1):Abstract S794.
28. Rawstron AC, Böttcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual dis- ease monitoring in CLL. Leukemia. 2013;27(1):142-149.
haematologica | 2019; 104(11)
2257


































































































   149   150   151   152   153